Background Clostridioides difficile infection (CDI) remains the leading cause of healthcare-
associated diarrhoea, despite existing guidelines for infection control measures and …

Abstract Recurrent Clostridioides (formerly Clostridium) difficile infection (rCDI) is common,
and patients who have had one recurrence are more likely to have multiple recurrences …

Background Faecal microbiota transplantation (FMT) is the standard treatment for patients
with multiple recurrent Clostridioides difficile infection (rCDI). Recently, new commercially …

Clostridioides difficile remains a problematic pathogen resulting in significant morbidity and
mortality, especially for high-risk groups that include immunocompromised patients. Both the …

Background We aimed to describe the frequency of use and effectiveness of bezlotoxumab
(BZX) and fecal microbiota transplantation (FMT) in patients with Clostridioides difficile …

Agents in development for the prevention or treatment of Clostridioides difficile infection can
be split into three broad categories: antibiotics, microbiome restoration, and vaccines. Given …

Introduction Effective treatments for recurrent Clostridioides difficile infection (rCDI) are
urgently needed. RBX2660 is an investigational microbiota-based live biotherapeutic to …

Objectives We aimed to assess the comparative efficacy and safety of adjunctive
interventions for the prevention of Clostridioides difficile recurrence. Methods We searched …

Abstract RBX2660 (fecal microbiota, live-jslm; REBYOTA®) is an emerging option for the
prevention of recurrent Clostridioides difficile infection (CDI) following standard of care …

Clostridioides difficile infection (CDI) is the leading cause of hospital-acquired diarrhea and
is common in the community. Both younger individuals who may be healthy otherwise and …